Dieses BRD4 Protein ist gelabelt mit His tag,DYKDDDDK Tag.
Applikation
Binding Studies (Bind), Screening Assay (ScA)
Produktmerkmale
The peptide corresponding to amino acids 333-460 that contains the bromodomain sequences of BRD4 (accession number NP_490597.1) was expressed in E. coli and contains an N-terminal His tag and C-terminal FLAG tag with an observed molecular weight of 20.9 kDa.
Crystallography grade
BRD4
Spezies: Human
Wirt: Insektenzellen
Recombinant
>95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot.
WB, ELISA, SDS, Crys
BRD4
Spezies: Human
Wirt: HEK-293 Cells
Recombinant
The purity of the protein is greater than 95 % as determined by SDS-PAGE and Coomassie blue staining.
Applikationshinweise
Recombinant BRD4 (333-460) is suitable for use in binding assays, inhibitor screening, and selectivity profiling.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Handhabung
Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Lagerung
-80 °C
Informationen zur Lagerung
Recombinant proteins in solution are temperature sensitive and must be stored at -80°C to prevent degradation.
Bromodomain-containing protein 4 (BRD4) belongs to the BET subclass of proteins, which are characterized by two N-terminal bromodomains and one ET (Extra Terminal) domain. BRDs associate with chromatin through their bromodomains that recognize acetylated histone lysine residues. Bromodomains function as 'readers' of these epigenetic histone marks and regulate chromatin structure and gene expression by linking associated proteins to the acetylated nucleosomal targets. The ET domain functions as a protein binding motif and exerts atypical serine-kinase activity. The BET family consists of at least four members in mouse and human, BRD2 (also referred to as FSRG1, RING3), BRD3 (FSRG2, ORFX), BRD4 (FSRG4, MCAP/HUNK1), and BRDT (FSRG3, BRD6). BRD proteins are related to the female Sterile Homeotic protein gene in Drosophila, a gene required maternally for proper expression of other homeotic genes, such as Ubx, which is involved in pattern formation. BRD4 has been identified recently as a therapeutic target in many cancers, including acute myeloid leukemia, multiple myeloma, Burkitt's lymphoma, NUT midline carcinoma, colon cancer, and breast cancer. BRD4 regulates the transcription of oncogenes, HIV, and human papilloma virus (HPV). It has been shown to bind and phosphorylate RNA pol II, which implicates its involvement in the regulation of eukaryotic transcription.